Rwanda’s nationwide rollout of long-acting injectable PrEP, Cabotegravir, marks a significant step forward in the fight against HIV/AIDS. However, this development highlights a deeper truth: ending HIV is not only a scientific challenge but also a social one rooted in the urgent need for zero discrimination. For decades, stigma has been one of the biggest barriers to HIV prevention and treatment. Communities most at risk, such as sex workers, men who have sex with men, and other marginalized groups, often face judgment, exclusion, and even criminalization. These realities discourage people from seeking testing, prevention tools, or care. In this context, the discreet and long-acting nature of injectable PrEP is transformative. It offers privacy, dignity, and autonomy, which are essential in environments where stigma affects health decisions. ALSO READ: Two-month HIV prevention injection set for nationwide rollout Yet, biomedical innovation alone cannot end HIV. Without addressing discrimination, even the most effective tools may fall short. The success of Cabotegravir will depend on whether health systems remain inclusive, respectful, and accessible to everyone, regardless of identity, profession, or social status. Healthcare providers must be trained not just to administer the injection, but also to offer non-judgmental, confidential services that build trust with patients. Rwanda has already shown leadership in public health, and this rollout offers another chance to connect innovation with equity. A zero-discrimination approach means making sure that no one is left behind; not in policy, not in clinics, and not in public discussion.
